Emergent BioSolutions Inc.

Deliver additional doses of AV7909 to the Strategic National Stockpile

Deadline passed; outcome being checked

Announced: 4 Nov 2021
Due: 31 Mar 2023
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“the Company expects to deliver additional doses of AV7909 over 18 months from the date of execution of the contract modification”

SourceEmergent BioSolutions Inc. Form 8-K press release, 2021-11-04
FilingSEC filing index
Deadline as statedover 18 months from the date of execution of the contract modification
Deadline used31 Mar 2023, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2021-EBS-002471
Cite as https://keptindex.org/c/KI-C-2021-EBS-002471/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Delivery
Indicative materiality: Medium rules
Action: Deliver
Deliverable: AV7909 doses
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High
Depends on: Customer

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-EBS-002471 · Corrections policy